New study tests biologic drug guselkumab for ulcerative colitis in chinese patients
NCT ID NCT07302360
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 Chinese patients with moderate-to-severe ulcerative colitis who have never taken biologic drugs. They will receive guselkumab as part of their normal care. Researchers will measure changes in symptoms and quality of life over 48 weeks to see how well the drug works in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (a biologic medicine given by injection)
What this could lead to
If successful, this study could show that guselkumab is a safe and effective treatment option for ulcerative colitis in patients who have not used biologics before.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also limited to Chinese patients, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzhou No 2 Peoples Hospital
RECRUITINGChangzhou, 213003, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
RECRUITINGNanjing, 223800, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100006, China
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
-
The First Affiliated Hospital Sun Yat-Sen University
RECRUITINGGuangzhou, 510080, China
-
The Second Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, 310009, China
-
The Second Hospital of Hebei Medical University
RECRUITINGShijiazhuang, 050000, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, China
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, 300052, China